Librela 15mg Injection for Dogs is a veterinary medicine used to help manage pain linked with canine osteoarthritis, a long-term degenerative joint disease that can affect comfort, movement and day-to-day confidence. The active ingredient in Librela 15mg Injection is bedinvetmab, a canine monoclonal antibody designed specifically for dogs. It is given by subcutaneous injection, usually once a month, by a veterinary professional or under veterinary direction.

Librela 15mg Injection can form part of a broader arthritis care plan that may also include weight management, controlled exercise, physiotherapy, joint supplements and regular veterinary reassessment. A calm, consistent plan is important because canine arthritis is usually managed over time rather than solved with one treatment.

Osteoarthritis in dogs often develops gradually, so it can be easy to mistake discomfort for normal ageing. Librela 15mg Injection may be discussed when a vet has examined your dog and identified clinical signs consistent with osteoarthritic pain. Dogs may show a mixture of physical and behavioural changes, and these can vary from day to day depending on activity, weather, bodyweight and the joints affected. Common signs that may prompt a vet to discuss Librela 15mg Injection include:

Your dog is stiff when rising after sleep or rest.
Your dog limps, lags behind on walks or shortens their stride.
Your dog struggles with stairs, jumping, turning or getting into the car.
Your dog seems less playful, less sociable or more sensitive when handled.
Your dog loses muscle tone because normal movement has become uncomfortable.

Librela 15mg Injection is used to reduce the impact of chronic osteoarthritis pain, helping dogs move more freely when pain is limiting their normal routine.

Librela 15mg Injection works differently from many traditional anti-inflammatory medicines. Bedinvetmab targets nerve growth factor, often shortened to NGF, which is involved in pain signalling within the body. In osteoarthritis, NGF can contribute to the way pain messages are generated and transmitted from affected joints. By binding to NGF, Librela 15mg Injection helps reduce NGF-mediated cell signalling, which can ease the perception of osteoarthritic pain. Because Librela 15mg Injection is a monoclonal antibody, it behaves more like a naturally occurring protein than a conventional small-molecule drug. It is broken down by normal protein catabolism into small peptides and amino acids, rather than relying heavily on liver enzyme pathways.

Librela 15mg Injection is for dogs only and should only be used after a veterinary assessment. It should not be used in dogs under 12 months of age, in animals intended for breeding, or in pregnant or lactating animals. It should also not be used if a dog is hypersensitive to bedinvetmab or any of the excipients in the injection. As with any veterinary medicine, side effects can occur. Mild injection site reactions may be seen, and owners should contact their vet if their dog appears unwell, develops facial swelling, marked itching, vomiting, diarrhoea, unusual lethargy, incoordination, changes in thirst or urination, appetite loss, urinary accidents, seizures or any other worrying sign after treatment. Librela 15mg Injection may be used alongside some other medicines under veterinary direction, but long-term combinations, particularly with non-steroidal anti-inflammatory drugs, should be considered carefully by the vet. A full medicines history, including supplements and recently stopped treatments, helps the vet make safer decisions.

How does Librela 15mg Injection work in dogs?
Librela 15mg Injection works by binding to nerve growth factor, known as NGF. NGF is involved in pain signalling, especially in joints affected by osteoarthritis. By reducing NGF-mediated signalling, bedinvetmab can help reduce osteoarthritic pain and improve comfort during normal movement.

How often is Librela 15mg Injection given?
Librela 15mg Injection is usually given once a month by subcutaneous injection. The dose and strength are based on the dog’s bodyweight and veterinary assessment. Your vet may review the response after the first and second doses before deciding whether to continue treatment.

How quickly can Librela 15mg Injection start to help?
Some dogs may show improvements in comfort or mobility within the first few weeks after Librela 15mg Injection, while others may need a second monthly dose before the response is clearer. Keeping notes on walking, rising, stairs and general behaviour can help your vet assess progress.

Can Librela 15mg Injection be used with other arthritis treatments?
Librela 15mg may be part of a wider arthritis plan that includes weight control, controlled exercise, physiotherapy, home adaptations and joint supplements. Any use alongside other medicines, especially long-term NSAIDs, should be directed by a vet who knows your dog’s clinical history.

What side effects should owners watch for after Librela 15mg Injection?
Owners should monitor for injection site swelling or warmth, unusual tiredness, vomiting, diarrhoea, changes in thirst or urination, appetite loss, incoordination, facial swelling, itching, urinary accidents or seizures. These signs do not mean every dog will react, but veterinary advice is important if they occur.